Sugi Predict

Sugi Predict / Targets / SMARCC1

SMARCC1

SWI/SNF complex subunit SMARCC1 · Q92922 · SMARCC1 on Sugi Atlas →

0 patent compounds predicted against SMARCC1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SMARCC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma PHASE2NOT_YET_RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) PHASE2ACTIVE_NOT_RECRUITING
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Cancer in Inherited Bone Marrow Failure Syndromes nanRECRUITING
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Palliative Care in Spinal Muscular Atrophy (SMA) 1 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SMARCC1 binder may also engage these)

ProteinNameSimilarity
P97496 — 1.000 P97496 →
SMARCC2 SWI/SNF complex subunit SMARCC2 1.000 landscape →
Q6PDG5 — 1.000 Q6PDG5 →
Q7PZD5 — 0.992 Q7PZD5 →
Q8TC92 — 0.992 Q8TC92 →
Q8K0V4 — 0.992 Q8K0V4 →
Q6PGA0 — 0.992 Q6PGA0 →
B4P6P7 — 0.992 B4P6P7 →
P35611 — 0.992 P35611 →
B4GAM1 — 0.991 B4GAM1 →
Q8BMP6 — 0.991 Q8BMP6 →
Q8BHR2 — 0.991 Q8BHR2 →
ASH2L Set1/Ash2 histone methyltransferase complex subunit ASH2 0.991 landscape →
B3MJ69 — 0.991 B3MJ69 →
B4MY63 — 0.991 B4MY63 →
A1ZAB5 — 0.991 A1ZAB5 →
P57094 — 0.991 P57094 →
B3H615 — 0.991 B3H615 →
B3MIW0 — 0.991 B3MIW0 →
Q9JHD2 — 0.991 Q9JHD2 →
Q80U87 — 0.991 Q80U87 →
U2SURP U2 snRNP-associated SURP motif-containing protein 0.990 landscape →
Q6DD45 — 0.990 Q6DD45 →
Q8WUB8 — 0.990 Q8WUB8 →
Q8VD37 — 0.990 Q8VD37 →
P48193 — 0.990 P48193 →
B4II37 — 0.990 B4II37 →
G5EEM9 — 0.990 G5EEM9 →
B4KT50 — 0.990 B4KT50 →
P61406 — 0.990 P61406 →